SG10201913099YA - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents

Dosage and administration of non-fucosylated anti-cd40 antibodies

Info

Publication number: SG10201913099YA
Authority: SG; Singapore
Prior art keywords: antibodies; dosage; administration; fucosylated anti; fucosylated
Prior art date: 2014-10-29

Application number

SG10201913099YA

Inventor

Shyra Gardai

Che-Leung Law

Stanford Peng

Jing Yang

Haley Neff-Laford

Original Assignee

Seattle Genetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-29

Filing date

2015-10-29

Publication date

2020-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858352&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913099Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-29 Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc

2020-02-27 Publication of SG10201913099YA publication Critical patent/SG10201913099YA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0009—Making of catheters or other medical or surgical tubes
- A61M25/0012—Making of catheters or other medical or surgical tubes with embedded structures, e.g. coils, braids, meshes, strands or radiopaque coils
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/002—Packages specially adapted therefor ; catheter kit packages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

SG10201913099YA 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies SG10201913099YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462072031P	2014-10-29	2014-10-29
US201562134955P	2015-03-18	2015-03-18

Publications (1)

Publication Number	Publication Date
SG10201913099YA true SG10201913099YA (en)	2020-02-27

Family

ID=55858352

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201913099YA SG10201913099YA (en)	2014-10-29	2015-10-29	Dosage and administration of non-fucosylated anti-cd40 antibodies
SG11201702598XA SG11201702598XA (en)	2014-10-29	2015-10-29	Dosage and administration of non-fucosylated anti-cd40 antibodies

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201702598XA SG11201702598XA (en)	2014-10-29	2015-10-29	Dosage and administration of non-fucosylated anti-cd40 antibodies

Country Status (22)

Country	Link
US (8)	US11213584B2 (en)
EP (2)	EP3212230B1 (en)
JP (5)	JP6691113B2 (en)
KR (1)	KR20170072884A (en)
CN (2)	CN107073118B (en)
AU (2)	AU2015339128C1 (en)
BR (1)	BR112017008959A2 (en)
CA (1)	CA2963720A1 (en)
CY (1)	CY1124033T1 (en)
DK (1)	DK3212230T3 (en)
EA (1)	EA036498B1 (en)
ES (1)	ES2864756T3 (en)
HK (1)	HK1243328A1 (en)
HU (1)	HUE054075T2 (en)
IL (2)	IL299075A (en)
MX (1)	MX2017005152A (en)
PL (1)	PL3212230T3 (en)
PT (1)	PT3212230T (en)
SG (2)	SG10201913099YA (en)
SI (1)	SI3212230T1 (en)
WO (1)	WO2016069919A1 (en)
ZA (2)	ZA201702347B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6691113B2 (en) *	2014-10-29	2020-04-28	シアトルジェネティックス，インコーポレイテッド	Dosage and administration of non-fucosylated anti-CD40 antibody
US20210001032A1 (en) *	2015-03-27	2021-01-07	Eliaz Therapeutics, Inc.	Galectin-3 plasmapheresis therapy
MX2018009700A (en)	2016-02-17	2019-01-24	Seattle Genetics Inc	Bcma antibodies and use of same to treat cancer and immunological disorders.
MX2018014630A (en)	2016-05-27	2019-06-10	Abbvie Biotherapeutics Inc	Anti-cd40 antibodies and their uses.
AU2017271601A1 (en)	2016-05-27	2018-12-13	Abbvie Biotherapeutics Inc.	Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US11905331B2 (en)	2016-11-11	2024-02-20	Kumho Ht, Inc.	Antibody binding specifically to CD40 and use thereof
EP3717515A2 (en)	2017-12-01	2020-10-07	Seattle Genetics, Inc.	Cd47 (masked) antibodies and uses thereof for treating cancer
US20210283168A1 (en) *	2018-03-13	2021-09-16	Hibercell, Inc.	Beta glucan and cd40 agonist combination immunotherapy
CA3103629A1 (en)	2018-06-15	2019-12-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
CA3107596A1 (en)	2018-08-23	2020-02-27	Seagen Inc.	Anti-tigit antibodies
CN113226357A (en)	2018-11-23	2021-08-06	斯特赖克药物公司	Bispecific conjugates
FR3089597B1 (en)	2018-12-06	2020-11-20	Gaztransport Et Technigaz	Sealed and thermally insulating tank
KR20210104837A (en) *	2018-12-19	2021-08-25	씨젠 인크.	Controlled Fucosylation of Antibodies
EP3941480A4 (en) *	2019-03-18	2023-04-26	Score Pharma, Inc.	Compounds for inhibiting fucosylation and methods for using the same
EP3962493A2 (en)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP3986426A4 (en) *	2019-06-21	2023-10-18	Board of Regents, The University of Texas System	Targeting alpha3beta1 integrin for treatment of cancer and other diseases
EP4027998A1 (en)	2019-09-09	2022-07-20	Basilea Pharmaceutica International AG	Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
JP2023509359A (en)	2019-12-17	2023-03-08	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	Combination anticancer therapy with inducers of iron-dependent cell degradation
TW202206100A (en)	2020-04-27	2022-02-16	美商西健公司	Treatment for cancer
GB202008003D0 (en)	2020-05-28	2020-07-15	Quine Medical Ab	Anti-CD40 antibody
CN116096906A (en)	2020-06-29	2023-05-09	旗舰创业创新五公司	Virus engineered to promote saenox delivery and use thereof in treating cancer
WO2022072523A1 (en)	2020-09-30	2022-04-07	Seagen Inc.	Uveal melanoma treatment using sea-cd40
CA3200974A1 (en)	2020-11-08	2022-05-12	Seagen Inc.	Combination therapy
US11883432B2 (en)	2020-12-18	2024-01-30	Century Therapeutics, Inc.	Chimeric antigen receptor system with adaptable receptor specificity
CA3214085A1 (en)	2021-03-31	2022-10-06	Darby Rye Schmidt	Thanotransmission polypeptides and their use in treating cancer
TW202314247A (en)	2021-05-25	2023-04-01	美商思進公司	Methods of quantifying anti-cd40 antibodies
KR20240026507A (en)	2021-06-29	2024-02-28	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	Immune cells engineered to promote thananotransmission and uses thereof
WO2023010080A1 (en)	2021-07-30	2023-02-02	Seagen Inc.	Treatment for cancer
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5874082A (en)	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
AU6934600A (en)	1999-08-27	2001-03-26	Board Of Regents, The University Of Texas System	Cd40 ligand and cd40 agonist compositions and methods of use
JP2003510371A (en)	1999-10-04	2003-03-18	カイロンコーポレイション	CD40 antagonist for treating psoriasis
AU2001259106A1 (en)	2000-04-19	2002-02-18	Tanox, Inc.	CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en)	2000-04-28	2006-06-20	Gemini Science, Inc.	Human anti-CD40 antibodies
DE60143535D1 (en)	2000-10-02	2011-01-05	Novartis Vaccines & Diagnostic	HUMAN ANTIBODIES AGAINST CD40
CA2658221C (en)	2001-04-27	2012-11-27	Kyowa Hakko Kirin Co., Ltd.	Anti-cd40 monoclonal antibody
AR039067A1 (en)	2001-11-09	2005-02-09	Pfizer Prod Inc	ANTIBODIES FOR CD40
US20080199471A1 (en)	2002-03-01	2008-08-21	Bernett Matthew J	Optimized cd40 antibodies and methods of using the same
US20050136055A1 (en)	2003-12-22	2005-06-23	Pfizer Inc	CD40 antibody formulation and methods
BRPI0610470A2 (en)	2005-05-26	2010-06-22	Seattle Genetics Inc	isolated antibody or antigen-binding fragment that specifically binds human cd40, kit, pharmaceutical composition, and isolated polynucleotide
BRPI0619586A2 (en) *	2005-12-09	2018-08-28	Seattle Genetics Inc	Method for treating or preventing a disorder associated with cd40
CA2647282A1 (en)	2006-04-05	2007-10-11	Pfizer Products Inc.	Ctla4 antibody combination therapy
CN101910414B (en)	2007-11-07	2016-01-13	健泰科生物技术公司	For assessment of the method and composition of the responsiveness of B cell lymphoma antagonism CD40 Antybody therapy
CA2712989C (en) *	2008-01-23	2015-10-27	Xencor, Inc.	Optimized cd40 antibodies and methods of using the same
EP2282773B1 (en) *	2008-05-02	2014-01-15	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20120258496A1 (en) *	2010-09-27	2012-10-11	Boehringer Ingelheim International Gmbh	Production of low fucose antibodies in h4-ii-e rat cells
AU2013201121A1 (en) *	2011-09-20	2013-04-04	Vical Incorporated	Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en)	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
JP6691113B2 (en) *	2014-10-29	2020-04-28	シアトルジェネティックス，インコーポレイテッド	Dosage and administration of non-fucosylated anti-CD40 antibody

2015
- 2015-10-29 JP JP2017522840A patent/JP6691113B2/en active Active
- 2015-10-29 CN CN201580059631.3A patent/CN107073118B/en active Active
- 2015-10-29 ES ES15854895T patent/ES2864756T3/en active Active
- 2015-10-29 WO PCT/US2015/058108 patent/WO2016069919A1/en active Application Filing
- 2015-10-29 SG SG10201913099YA patent/SG10201913099YA/en unknown
- 2015-10-29 EA EA201790932A patent/EA036498B1/en unknown
- 2015-10-29 EP EP15854895.8A patent/EP3212230B1/en active Active
- 2015-10-29 AU AU2015339128A patent/AU2015339128C1/en active Active
- 2015-10-29 SI SI201531569T patent/SI3212230T1/en unknown
- 2015-10-29 IL IL299075A patent/IL299075A/en unknown
- 2015-10-29 HU HUE15854895A patent/HUE054075T2/en unknown
- 2015-10-29 SG SG11201702598XA patent/SG11201702598XA/en unknown
- 2015-10-29 BR BR112017008959-9A patent/BR112017008959A2/en not_active Application Discontinuation
- 2015-10-29 KR KR1020177009766A patent/KR20170072884A/en not_active IP Right Cessation
- 2015-10-29 US US15/522,614 patent/US11213584B2/en active Active
- 2015-10-29 MX MX2017005152A patent/MX2017005152A/en unknown
- 2015-10-29 DK DK15854895.8T patent/DK3212230T3/en active
- 2015-10-29 PT PT158548958T patent/PT3212230T/en unknown
- 2015-10-29 CN CN202210123399.7A patent/CN114522228A/en active Pending
- 2015-10-29 EP EP20212733.8A patent/EP3831847A1/en active Pending
- 2015-10-29 CA CA2963720A patent/CA2963720A1/en active Pending
- 2015-10-29 PL PL15854895T patent/PL3212230T3/en unknown
2017
- 2017-01-20 US US15/411,741 patent/US11202827B2/en active Active
- 2017-04-03 ZA ZA2017/02347A patent/ZA201702347B/en unknown
- 2017-04-04 IL IL251552A patent/IL251552B2/en unknown
2018
- 2018-02-27 HK HK18102794.4A patent/HK1243328A1/en unknown
2020
- 2020-01-06 JP JP2020000194A patent/JP6833080B2/en active Active
- 2020-09-08 JP JP2020150669A patent/JP7165166B2/en active Active
2021
- 2021-03-11 JP JP2021039216A patent/JP2021088609A/en not_active Withdrawn
- 2021-04-01 ZA ZA2021/02219A patent/ZA202102219B/en unknown
- 2021-04-16 CY CY20211100334T patent/CY1124033T1/en unknown
- 2021-04-20 AU AU2021202407A patent/AU2021202407A1/en active Pending
2022
- 2022-04-25 US US17/728,350 patent/US20220249662A1/en not_active Abandoned
- 2022-05-02 US US17/734,541 patent/US20220265822A1/en not_active Abandoned
- 2022-11-02 US US17/979,582 patent/US20230201343A1/en not_active Abandoned
- 2022-11-09 US US17/983,970 patent/US20230201344A1/en not_active Abandoned
2023
- 2023-07-12 JP JP2023114493A patent/JP2023126406A/en active Pending
- 2023-09-20 US US18/471,051 patent/US20240075135A1/en active Pending
- 2023-09-20 US US18/471,036 patent/US20240075134A1/en active Pending

Also Published As

Publication number	Publication date
CY1124033T1 (en)	2022-05-27
CN107073118B (en)	2022-03-01
SG11201702598XA (en)	2017-05-30
SI3212230T1 (en)	2021-08-31
US11202827B2 (en)	2021-12-21
ES2864756T3 (en)	2021-10-14
PL3212230T3 (en)	2021-07-26
BR112017008959A2 (en)	2018-01-16
JP2023126406A (en)	2023-09-07
MX2017005152A (en)	2017-08-04
US20220265822A1 (en)	2022-08-25
EA201790932A1 (en)	2017-08-31
CA2963720A1 (en)	2016-05-06
JP7165166B2 (en)	2022-11-02
EP3212230A4 (en)	2018-06-20
US20220249662A1 (en)	2022-08-11
JP2020200343A (en)	2020-12-17
JP6833080B2 (en)	2021-02-24
US20170333556A1 (en)	2017-11-23
EP3831847A1 (en)	2021-06-09
US20230201344A1 (en)	2023-06-29
PT3212230T (en)	2021-04-19
WO2016069919A1 (en)	2016-05-06
JP6691113B2 (en)	2020-04-28
KR20170072884A (en)	2017-06-27
US20230201343A1 (en)	2023-06-29
EP3212230A1 (en)	2017-09-06
JP2020050677A (en)	2020-04-02
AU2021202407A1 (en)	2021-05-20
JP2017533909A (en)	2017-11-16
HK1243328A1 (en)	2018-07-13
HUE054075T2 (en)	2021-08-30
AU2015339128A1 (en)	2017-04-20
JP2021088609A (en)	2021-06-10
AU2015339128C1 (en)	2021-12-16
CN107073118A (en)	2017-08-18
US20170137528A1 (en)	2017-05-18
ZA202102219B (en)	2022-10-26
US20240075135A1 (en)	2024-03-07
IL251552B1 (en)	2023-01-01
IL251552B2 (en)	2023-05-01
IL299075A (en)	2023-02-01
EA036498B1 (en)	2020-11-17
US20240075134A1 (en)	2024-03-07
ZA201702347B (en)	2021-07-28
AU2015339128B2 (en)	2021-01-21
DK3212230T3 (en)	2021-04-19
IL251552A0 (en)	2017-05-29
US11213584B2 (en)	2022-01-04
EP3212230B1 (en)	2021-01-20
CN114522228A (en)	2022-05-24

Publication	Publication Date	Title
ZA202102219B (en)	2022-10-26	Dosage and administration of non-fucosylated anti-cd40 antibodies
HK1257056A1 (en)	2019-10-11	Anti-dll3 antibody drug conjugates and methods of use
IL259713A (en)	2018-07-31	Anti-dr5 antibodies and methods of use thereof
ZA201606630B (en)	2020-12-23	Anti-ox40 antibodies and methods of use
GB201701039D0 (en)	2017-03-08	Vertically integrated continuous delivery of an application
PL3487505T3 (en)	2023-10-09	Administration and dosage of diaminophenothiazines
PL3191167T3 (en)	2020-01-31	Valve for administration of drug fluids
IL246489A0 (en)	2016-08-31	Methods of using anti-steap1 antibodies and immunoconjugates
GB201419540D0 (en)	2014-12-17	Delivery of drugs
HK1223630A1 (en)	2017-08-04	Dosage and administration anti-egfr therapeutics -egfr
ZA201701492B (en)	2022-05-25	Pyrazolothiazole compound and medicine
HRP20181406T1 (en)	2018-10-19	Pharmaceutical dosage forms
GB201612863D0 (en)	2016-09-07	Administration and dosage of diaminophenothiazines
GB201415486D0 (en)	2014-10-15	Infusion package and method of manufature
GB201409644D0 (en)	2014-07-16	Inhalers and dosing devices for inhalers
GB201409272D0 (en)	2014-07-09	Synergistic combination of analgesic drugs